CLPT ClearPoint Neuro Inc

Price (delayed)

$14.97

Market cap

$456.65M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.17

Enterprise value

$491.23M

?
Relative Growth: Rel. Growth: 37
Relative Strength: Rel. Strength: 63
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 17

ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The Company uniquely provides both established clinical products as well as pre-clinical ...

Highlights
The gross profit has grown by 30% YoY and by 4.6% from the previous quarter
ClearPoint Neuro's revenue has increased by 26% YoY and by 4.1% from the previous quarter
CLPT's debt has soared by 80% YoY
ClearPoint Neuro's net income has plunged by 56% YoY and by 19% from the previous quarter

Key stats

What are the main financial stats of CLPT

CLPT stock price

How has the ClearPoint Neuro stock price performed over time
Intraday
-5.19%
1 week
11.72%
1 month
-2.73%
1 year
23.11%
YTD
9.43%
QTD
-16.09%

Financial performance

How have ClearPoint Neuro's revenue and profit performed over time
Revenue
$42.28M
Gross profit
$26.47M
Operating income
-$31.04M
Net income
-$34.57M
Gross margin
62.6%
Net margin
-81.8%
ClearPoint Neuro's net income has plunged by 56% YoY and by 19% from the previous quarter
The company's operating income fell by 37% YoY and by 17% QoQ
The gross profit has grown by 30% YoY and by 4.6% from the previous quarter
ClearPoint Neuro's revenue has increased by 26% YoY and by 4.1% from the previous quarter

Price vs fundamentals

How does CLPT's price correlate with its fundamentals

Growth

What is ClearPoint Neuro's growth rate over time

Valuation

What is ClearPoint Neuro stock price valuation
P/E
N/A
P/B
41.66
P/S
10.68
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.62
ClearPoint Neuro's EPS has decreased by 44% YoY and by 17% from the previous quarter
The P/B is 50% above the last 4 quarters average of 29.2
The equity has contracted by 45% YoY and by 43% from the previous quarter
ClearPoint Neuro's revenue has increased by 26% YoY and by 4.1% from the previous quarter
The price to sales (P/S) is 6% lower than the last 4 quarters average of 12.0

Efficiency

How efficient is ClearPoint Neuro business performance
The return on equity has dropped by 99% year-on-year and by 33% since the previous quarter
ClearPoint Neuro's return on invested capital has surged by 59% YoY but it has decreased by 2.4% QoQ
CLPT's ROA is up by 21% YoY but it is down by 11% from the previous quarter
ClearPoint Neuro's ROS has decreased by 13% from the previous quarter and by 12% YoY

Dividends

What is CLPT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CLPT.

Financial health

How did ClearPoint Neuro financials performed over time
The company's total assets is 14% higher than its total liabilities
ClearPoint Neuro's total liabilities has soared by 76% YoY
The quick ratio has contracted by 41% YoY and by 22% from the previous quarter
CLPT's debt has soared by 80% YoY
The debt to equity has surged by 76% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.